Severe Acute Respiratory Syndrome Type 2-Causing Coronavirus: Variants and Preventive Strategies

COVID-19 vaccines have constituted a substantial scientific leap in countering severe acute respiratory syndrome type 2-causing coronavirus (SARS-CoV-2), and worldwide implementation of vaccination programs has significantly contributed to the global pandemic effort by saving many lives. However, the continuous evolution of the SARS-CoV-2 viral genome has resulted in different variants with a diverse range of mutations, some with enhanced virulence compared with previous lineages. Such variants are still a great concern as they have the potential to reduce vaccine efficacy and increase the viral transmission rate. This review summarizes the significant variants of SARS-CoV-2 encountered to date (December 2021) and discusses a spectrum of possible preventive strategies, with an emphasis on physical and materials science

Metal-based nanoparticles for combating antibiotic resistance

The resistance to antibiotics in combating bacteria is a serious worldwide problem. The search for new approaches to address antibacterial resistance is therefore of crucial importance and seeking alternatives for the treatment and control of bacterial diseases associated with resistant strains, which is in need of urgent action. There is an ongoing interest in metal-based nanoparticles (MBNPs) and their usage synergy with antibiotics due to their unique properties, such as overcoming bacterial resistance, reducing acute toxicity compared to their sizes, and allowing dosage reduction of active pharmaceutical ingredients. Combining MBNPs and antibiotics not only enhances the antibacterial effect but also allows the inhibition of biofilm production. Furthermore, MBNPs and antibiotics incorporated in polymeric biomaterial matrix have been widely studied to improve their efficiency and devoid the resistance. However, these studies need to be combined in a literature review. Polymeric biomaterials offer high mechanical stability with improved biocompatibility. Moreover, their use makes a single dose of administration of the final product with extended antibiotic half-life possible while slowly releasing their reservoir, which is an advantage in continuously combating resistance. This review focuses on different promising biomedical strategies for enhancing the bactericidal efficacy of antibiotics by the synergistic use of MBNPs, antibiotics, and polymeric biomaterials together to combat the resistance of different bacterial strains. In addition, it is prospected to guide opportunities for new research for future biomedical applications

Co-Culture of Keratinocyte-Staphylococcus aureus on Cu-Ag-Zn/CuO and Cu-Ag-W Nanoparticle Loaded Bacterial Cellulose:PMMA Bandages

Pressurized gyration and its sister processes are novel methods to produce polymeric fibers. Potential applications for such fibers include wound dressings, tissue engineering scaffolds, and filters. This study reports on a pressurized gyration technique that employs pressured N2 gas to prepare biocompatible wound dressing bandages from bacterial cellulose and poly (methylmethacrylate) polymer blended with alloyed antimicrobial nanoparticles. Resulting bandages are manufactured with high product yield and characterized for their chemical, physical, and mechanical properties. Increased density in solutions with additional antimicrobial nanoparticles results in increased fiber diameters. Also, addition of antimicrobial nanoparticles enhances ultimate tensile strength and Young's modulus of the bandages. Typical molecular bonding in the bandages is confirmed by Fourier-transform infrared spectroscopy, with peaks that have higher intensity and narrowing points being caused by additional antimicrobial nanoparticles. More so, the cellular response to the bandages and the accompanying antimicrobial activity are studied in detail by in vitro co-culture of Staphylococcus aureus and keratinocytes. Antimicrobial nanoparticle-loaded bandage samples show increased cell viability and bacteria inhibition during co-culture and are found to have a promising future as epidermal wound dressing materials

Production of the biomimetic small diameter blood vessels for cardiovascular tissue engineering

© 2018 Taylor & Francis A novel biomimetic vascular graft scaffolds were produced by electrospinning method with the most superior characteristics to be a proper biomimetic small diameter blood vessel using Polycaprolactone(PCL), Ethyl Cellulose(EC) and Collagen Type-1 were used to create the most convenient synergy of a natural and synthetic polymer to achieve similarity to native small diameter blood vessels. Scanning Electron Microscopy(SEM), Fourier Transform Infrared Spectroscopy(FTIR), Differential Scanning Calorimetry Analysis(DSC), tensile measurement tests, and in-vitro and in-vivo applications were performed. Results indicated significant properties such as having 39.33 nm minimum, 104.98 nm average fiber diameter, 3.2 MPa young modulus and 135% relative cell viability

Bioinspired scaffold induced regeneration of neural tissue

In the last decade, nerve tissue engineering has attracted much attention due to the incapability of self-regeneration. Nerve tissue regeneration is mainly based on scaffold induced nanofibrous structures using both bio and synthetic polymers. The produced nanofibrous scaffolds have to be similar to the natural extracellular matrix and should provide an appropriate environment for cells to attach onto. Nanofibrous scaffolds can support or regenerate cells of tissue. Electrospinning is an ideal method for producing the nanofibrous scaffolds. In this study, Bacterial cellulose (BC)/Poly (ε-caprolactone) (PCL) blend nanofibrous scaffolds were successfully prepared by electrospinning for nerve tissue induced repair. The produced nanofibrous scaffolds contain well defined interconnected nanofiber networks with hollow micro/nanobeads. Firstly, in-vitro biocompatibilities of nanofibrous scaffolds were tested with L2929 murine fibroblasts and improved cell adhesion and proliferation was observed with polymer blends compared with PCL only. The primary cell culture was performed with dorsal root ganglia (DRG) cells on nanofibrous samples and the samples were found suitable for enhancing neural growth and neurite outgrowth. Based on these results, the BC/PCL (50:50 wt.%) nanofibrous scaffolds exhibited nerve-like branching and are excellent candidate for potential biomimetic applications in nerve tissue engineering regeneration

year Turkish experience in cladribine therapy

In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy ( 95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population. Copyright (C) 2014 John Wiley & Sons, Ltd

Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.

In this multicenter retrospective analysis, we aimed to present clinical, laboratory and treatment results of 94 patients with Hairy cell leukemia diagnosed in 13 centers between 1990 and 2014. Sixty-six of the patients were males and 28 were females, with a median age of 55. Splenomegaly was present in 93.5% of cases at diagnosis. The laboratory findings that came into prominence were pancytopenia with grade 3 bone marrow fibrosis. Most of the patients with an indication for treatment were treated with cladribine as first-line treatment. Total and complete response of cladribine was 97.3% and 80.7%. The relapse rate after cladribine was 16.6%, and treatment related mortality was 2.5%. Most preferred therapy (95%) was again cladribine at second-line, and third line with CR rate of 68.4% and 66.6%, respectively. The 28-month median OS was 91.7% in all patients and 25-month median OS 96% for patients who were given cladribine as first-line therapy. In conclusion, the first multicenter retrospective Turkish study where patients with HCL were followed up for a long period has revealed demographic characteristics of patients with HCL, and confirmed that cladribine treatment might be safe and effective in a relatively large series of the Turkish study population